VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The important role of bispecific antibodies in the future treatment of R/R DLBCL

In this video, Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, briefly discusses the need to improve treatment approaches for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of bispecific antibodies and their potential role in the DLBCL treatment armamentarium. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter